Freshfields advises HUTCHMED on the divestment of its 45% equity in Shanghai Hutchison Pharmaceuticals Limited

Global law firm Freshfields is advising HUTCHMED (China) Limited (‘HUTCHMED’) on the divestment of its 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited for approximately US$608 million (RMB4,478 million) in cash, to GP Health Service Capital Co., Ltd and Shanghai Pharmaceuticals Holding Co., Ltd. The transaction constitutes a major transaction of HUTCHMED under the Hong Kong Listing Rules and is subject to various conditions, including approval of shareholders of HUTCHMED at an extraordinary general meeting. Additional information is available here.

HUTCHMED is a biopharmaceutical company listed on the Hong Kong Stock Exchange (stock code: 13), the AIM market of the London Stock Exchange (stock code: HCM) and in the form of American depositary shares on the NASDAQ Global Select Market (ticker symbol: HCM).

The Freshfields team advising as the Hong Kong counsel on the transaction was led by partner Grace Huang with support from counsel Cindy Kwong, and associate Kristy Wong.